PMID- 16757434
OWN - NLM
STAT- MEDLINE
DCOM- 20060718
LR  - 20181113
IS  - 0925-5710 (Print)
IS  - 0925-5710 (Linking)
VI  - 83
IP  - 4
DP  - 2006 May
TI  - Primary mediastinal large B-cell lymphoma: a single-center study of 
      clinicopathologic characteristics.
PG  - 331-6
AB  - Primary mediastinal large B-cell lymphoma (PMLBCL) is a subset of LBCL with 
      unique clinicopathologic features. Some studies have raised the question of 
      differences in biological features and clinical course among patients from 
      different parts of the world. We conducted a retrospective clinicopathologic 
      analysis of 24 patients with PMLBCL from a single center in Croatia. We also 
      conducted the first investigation of the frequency of lymphotropic viruses human 
      herpesvirus 6 (HHV-6) and HHV-8 in lymphoid lesions of this disease. The clinical 
      characteristics of the patients were as expected, with high International 
      Prognostic Index scores, elevated serum lactate dehydrogenase (LDH) levels, and 
      bulky disease being adverse prognostic factors. Only 6 patients (25%) showed CD30 
      expression, and Bcl-6 protein expression was, in our series, prognostically 
      favorable (P = .0401). One patient's tumor had detectable HHV-6 genome sequence, 
      but no HHV-8 sequences were detected in any tumors. Two thirds of the patients 
      received CHOP chemotherapy (cyclophosphamide, hydroxydaunomycin, vincristine, and 
      prednisone) with a relatively low complete remission rate (43.8%; median 
      follow-up, 33.8 months). This study confirmed the moderate preponderance among 
      PMLBCL patients of young females with B symptoms and elevated LDH levels. The 
      CHOP regimen proved effective as first-line therapy only in patients with limited 
      disease. Therefore, other third-generation chemotherapy protocols may be 
      considered for treatment, especially in patients with bulky and advanced disease.
FAU - Kolonic, Slobodanka Ostojic
AU  - Kolonic SO
AD  - Department of Internal Medicine, Merkur University Hospital, Zagreb, Croatia. 
      ostojic@net.hr
FAU - Dzebro, Sonja
AU  - Dzebro S
FAU - Kusec, Rajko
AU  - Kusec R
FAU - Planinc-Peraica, Ana
AU  - Planinc-Peraica A
FAU - Dominis, Mara
AU  - Dominis M
FAU - Jaksic, Branimir
AU  - Jaksic B
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
RN  - 0 (BCL6 protein, human)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Ki-1 Antigen)
RN  - 0 (Proto-Oncogene Proteins c-bcl-6)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
RN  - VB0R961HZT (Prednisone)
RN  - CHOP protocol
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage
MH  - Cyclophosphamide/administration & dosage
MH  - DNA-Binding Proteins/biosynthesis
MH  - Doxorubicin/administration & dosage
MH  - Female
MH  - Follow-Up Studies
MH  - Gene Expression Regulation, Leukemic
MH  - Genome, Viral
MH  - Herpesvirus 6, Human
MH  - Herpesvirus 8, Human
MH  - Humans
MH  - Ki-1 Antigen/biosynthesis
MH  - L-Lactate Dehydrogenase/blood
MH  - Lymphoma, B-Cell/*blood/drug therapy/*pathology/virology
MH  - Lymphoma, Large B-Cell, Diffuse/*blood/drug therapy/*pathology/virology
MH  - Male
MH  - Mediastinal Neoplasms/*blood/drug therapy/*pathology
MH  - Middle Aged
MH  - Prednisone/administration & dosage
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-bcl-6
MH  - Retrospective Studies
MH  - Roseolovirus Infections/blood/pathology
MH  - Sex Factors
MH  - Vincristine/administration & dosage
EDAT- 2006/06/08 09:00
MHDA- 2006/07/19 09:00
CRDT- 2006/06/08 09:00
PHST- 2006/06/08 09:00 [pubmed]
PHST- 2006/07/19 09:00 [medline]
PHST- 2006/06/08 09:00 [entrez]
AID - Q41718174238504X [pii]
AID - 10.1532/IJH97.E0529 [doi]
PST - ppublish
SO  - Int J Hematol. 2006 May;83(4):331-6. doi: 10.1532/IJH97.E0529.